beta

ALLO

Allogene Therapeutics, Inc.

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam on November 2017 and is headquartered in South San Francisco, CA.

Market Cap: 3.8 Billion

Primary Exchange: NASDAQ

Website: http://www.allogene.com

Shares Outstanding: 122 Million

Float: 47.6 Million

Dividend: (%)

Beta: 1.09459483184353

Sector: Health Technology

Industry: Biotechnology

Ethical Flags

Longest drawdown: 286 trading days

From: 2018-11-06 To: 2019-12-09

Lowest Point:

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud